Earnings Reports: Johnson & Johnson (JNJ)
Earnings Date: July 18
Earnings Growth: 3.4%
Johnson & Johnson (NYSE:JNJ) has gained 14% so far this year and, despite that climb, sports a 2.6% dividend. JNJ also reports earnings on July 18 and is expected to report meager but steady growth. For the most recent three-month period, earnings of $1.80 per share are expected — roughly 3% higher than a year ago. That’s on par with the consensus from analysts three months back as well.
Johnson & Johnson has beat earnings in each of its previous four quarterly reports and has a long, impressive track record of cranking out consistent results.
On top of that, JNJ just got an FDA approval of its psoriasis drug Tremfya. While that news won’t impact the actual earnings result, monitor management’s expectations during the call.
Hilary Kramer is the editor of GameChangers, Breakout Stocks, High Octane Trader, Absolute Capital Return and Value Authority. She is an accomplished investment specialist and market strategist with more than 25 years of experience in portfolio management, equity research, trading, and risk management. She has extensive expertise in global financial management, asset allocation, investment banking and private equity ventures, and is regularly sought after to provide her analysis on Bloomberg, CNBC, Fox Business Network and other media.